
Jan 8 (Reuters) - Plus Therapeutics Inc PSTV.O:
PLUS THERAPEUTICS ANNOUNCES READ OUT OF TYPE B MEETING WITH THE FDA WITH GOAL OF ACCELERATING APPROVAL OF REYOBIQ™ FOR LEPTOMENINGEAL METASTASES
PLUS THERAPEUTICS INC - FDA INDICATES ACCELERATED APPROVAL MAY BE APPROPRIATE FOR LM
PLUS THERAPEUTICS INC - FDA RECOMMENDS STUDY EVALUATE ENDPOINT WITH CLINICAL BENEFIT
PLUS THERAPEUTICS INC - FDA CONVEYS MULTIPLE HISTOLOGIES MAY BE INCORPORATED IN TRIAL